A Phase III, multicenter, randomized, double-blind, placebo controlled, parallel group study to assess the efficacy and safety of KRP-116D in Japanese patients with interstitial cystisis.
Phase of Trial: Phase III
Latest Information Update: 02 Aug 2017
At a glance
- Drugs KRP-116D (Primary)
- Indications Interstitial cystitis
- Focus Therapeutic Use
- Sponsors Kyorin Pharmaceutical
- 01 Aug 2017 Status changed from not yet recruiting to recruiting.
- 19 May 2017 New trial record